Literature DB >> 3859711

Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia.

A M Carella, G Santini, D Giordano, F Frassoni, M Martinengo, A Congiu, S Nati, M Risso, R Cerri, A Marmont.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3859711     DOI： 10.1016/0145-2126(85)90144-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  4 in total

1.  Phase II trial of idarubicin in patients with advanced lymphoma.

Authors:  H Gillies; R Liang; H Rogers; P Harper; L Parapia; G Cox; S Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.

Authors:  F Ganzina; M A Pacciarini; N Di Pietro
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

Review 4.  Etoposide: current status and future perspectives in the management of malignant neoplasms.

Authors:  C P Belani; L A Doyle; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.